What is the common name of Guanfacine in the Chinese market?

Guanfacine was first marketed in the United States under the trade name Intuniv. It is mainly used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. As clinical demand increases, this drug is gradually introduced to other countries and regions, including the Chinese market. Currently, in China, guanfacine is registered and sold under the generic name of guanfacine hydrochloride extended-release tablets, which belongs to the category of prescription drugs.

Due to the relatively short time it has been on the market in China and the fact that supply channels are still gradually improving, patients may temporarily have inconvenience in purchasing it in some areas. However, as the national drug centralized procurement policy advances and more companies enter production, the accessibility of Guanfacine Hydrochloride Sustained-Release Tablets is expected to gradually increase in the future, and patients' medication burden may also be reduced.

Compared with foreign markets, the domestic version of guanfacine remains consistent in ingredients and dosage forms. It is also a sustained-release preparation, which can release the drug smoothly in the body and avoid adverse reactions caused by a rapid increase in blood concentration. Its treatment population mainly focuses on children and adolescentsADHD patients, and some doctors will also try to use it for individualized treatment of anxiety or sleep disorders under special circumstances.

It should be pointed out that although it has been approved for marketing in China, guanfacine has not yet been included in the scope of medical insurance reimbursement, which has increased the financial pressure on patients to a certain extent. Therefore, some families will try to purchase original drugs or generic drugs from overseas channels. However, this method involves uncertainties and risks, and it is not recommended to use it casually. In contrast, domestically registered Guanfacine Hydrochloride Sustained-release Tablets have more advantages in drug supervision, quality assurance and legal compliance. In the future, with the expansion of the application population and the strengthening of policy support, the popularity of guanfacine in the Chinese market will gradually increase, thereby providing more standardized treatment options for ADHD patients.

Reference materials:https://go.drugbank.com/drugs/DB01018